A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
University of California, San Francisco
Bristol-Myers Squibb
OHSU Knight Cancer Institute
Duke University
Duke University
Case Comprehensive Cancer Center